Clevidipine butyrate CAS NO.167221-71-8

The injectable antihypertensive drug Clovedipine Butyrate is an innovative injectable antihypertensive drug originally developed by AstraZeneca in the UK, with the trade name Cleviprex. It is used to treat acute hypertension and has a lasting effect of 72 hours. It can be used when oral medication is ineffective or inconvenient for patients to use, and its effect is rapid. Unlike existing hypertension drugs that are metabolized through the kidneys or liver, Clovedipine Butyrate is metabolized in the blood and does not accumulate in the body, making it particularly suitable for patients with advanced organ damage. The Medicines Company in the United States has global market development and commercialization licenses outside of Japan, and first launched this product in the United States on August 11, 2008. Clovedipine formulation is an injectable emulsion that needs to be stored in a refrigerator at 2-8 ℃, which may have adverse effects on sales. The above information was edited and organized by Xiaonan from Chemicalbook. Pharmacological action: Clovedipine, a dihydropyridine derivative, is an ultra short acting calcium channel blocker for intravenous injection. It was previously developed by AstraZeneca as a short-term control drug for perioperative hypertension, but development was temporarily discontinued. Clovedipine has high vascular and myocardial selectivity and is rapidly metabolized into inactive substances in the body. Clovedipine has a strong activity in reducing pulse rate and has a dilating effect on systemic and pulmonary blood vessels. In 2002, Medicines obtained authorization for this product from AstraZeneca. On August 1, 2008, the US Food and Drug Administration's Chemicalbook Administration FDA approved The Medicines company's intravenous preparation, Clovedipine Butyrate Injection Emulsion (Cleveiprex), for use in the treatment of hypertension when oral formulations are not suitable or desired. This product is another new type of intravenous antihypertensive drug approved by the US FDA 10 years later, representing a major progress in current hypertension treatment. It can quickly and accurately control blood pressure in critical care. According to comprehensive data from emergency rooms, operating rooms, and intensive care units, the launch of Clovedipine Butyrate will provide new and important clinical tools for doctors to control patient blood pressure. According to clinical research information, this product has fast onset and elimination of effects, and can accurately control blood pressure by increasing the dosage. Unlike many current intravenous antihypertensive drugs that are metabolized through the kidneys and/or liver, they are metabolized in the blood and tissues and therefore do not accumulate in the body. Lovidipine is a dihydropyridine L-type calcium channel blocker. L-type calcium channel regulates calcium inflow during depolarization of arterial smooth muscle. Experiments in anesthetized rats and dogs show that this product can reduce the average arterial blood pressure by reducing systemic vascular resistance. This product cannot reduce heart filling pressure, confirming that it has no effect on venous volume and blood vessels. This product was first approved for marketing in the United States based on the results of six Phase III clinical studies on 1406 patients undergoing treatment and surgery. All Phase III clinical studies met their primary endpoint indicators. This product can cause systemic hypotension and reflex tachycardia, with the most common adverse reactions (>2%) being headache, nausea, and vomiting.

The injectable antihypertensive drug Clovedipine Butyrate is an innovative injectable antihypertensive drug originally developed by AstraZeneca in the UK, with the trade name Cleviprex. It is used to treat acute hypertension and has a lasting effect of 72 hours. It can be used when oral medication is ineffective or inconvenient for patients to use, and its effect is rapid. Unlike existing hypertension drugs that are metabolized through the kidneys or liver, Clovedipine Butyrate is metabolized in the blood and does not accumulate in the body, making it particularly suitable for patients with advanced organ damage. The Medicines Company in the United States has global market development and commercialization licenses outside of Japan, and first launched this product in the United States on August 11, 2008. Clovedipine formulation is an injectable emulsion that needs to be stored in a refrigerator at 2-8 ℃, which may have adverse effects on sales. The above information was edited and organized by Xiaonan from Chemicalbook. Pharmacological action: Clovedipine, a dihydropyridine derivative, is an ultra short acting calcium channel blocker for intravenous injection. It was previously developed by AstraZeneca as a short-term control drug for perioperative hypertension, but development was temporarily discontinued. Clovedipine has high vascular and myocardial selectivity and is rapidly metabolized into inactive substances in the body. Clovedipine has a strong activity in reducing pulse rate and has a dilating effect on systemic and pulmonary blood vessels. In 2002, Medicines obtained authorization for this product from AstraZeneca. On August 1, 2008, the US Food and Drug Administration's Chemicalbook Administration FDA approved The Medicines company's intravenous preparation, Clovedipine Butyrate Injection Emulsion (Cleveiprex), for use in the treatment of hypertension when oral formulations are not suitable or desired. This product is another new type of intravenous antihypertensive drug approved by the US FDA 10 years later, representing a major progress in current hypertension treatment. It can quickly and accurately control blood pressure in critical care. According to comprehensive data from emergency rooms, operating rooms, and intensive care units, the launch of Clovedipine Butyrate will provide new and important clinical tools for doctors to control patient blood pressure. According to clinical research information, this product has fast onset and elimination of effects, and can accurately control blood pressure by increasing the dosage. Unlike many current intravenous antihypertensive drugs that are metabolized through the kidneys and/or liver, they are metabolized in the blood and tissues and therefore do not accumulate in the body. Lovidipine is a dihydropyridine L-type calcium channel blocker. L-type calcium channel regulates calcium inflow during depolarization of arterial smooth muscle. Experiments in anesthetized rats and dogs show that this product can reduce the average arterial blood pressure by reducing systemic vascular resistance. This product cannot reduce heart filling pressure, confirming that it has no effect on venous volume and blood vessels. This product was first approved for marketing in the United States based on the results of six Phase III clinical studies on 1406 patients undergoing treatment and surgery. All Phase III clinical studies met their primary endpoint indicators. This product can cause systemic hypotension and reflex tachycardia, with the most common adverse reactions (>2%) being headache, nausea, and vomiting.